目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Anaphylaxis - Overview
Anaphylaxis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Anaphylaxis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anaphylaxis - Companies Involved in Therapeutics Development
Allakos Inc
Aquestive Therapeutics Inc
ARS Pharmaceuticals Inc
BioArdis LLC
Bryn Pharma LLC
Crossject SA
Hoth Therapeutics Inc
Klaria Pharma Holding AB
Nasus Pharma Ltd
Orexo AB
Pharmacin BV
PureIMS BV
Anaphylaxis - Drug Profiles
AK-006 - Drug Profile
Product Description
Mechanism Of Action
AQST-109 - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
History of Events
epinephrine - Drug Profile
Product Description
Mechanism Of Action
HLK-0006 - Drug Profile
Product Description
Mechanism Of Action
HT-KIT - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
MRGPRX2 Antagonist - Drug Profile
Product Description
Mechanism Of Action
OX-640 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Anaphylaxis - Dormant Projects
Anaphylaxis - Product Development Milestones
Featured News & Press Releases
Sep 13, 2022: Bryn Pharma announces completion of its pivotal study comparing UTULY epinephrine intranasal spray vs. 0.3 mg epinephrine autoinjector for the treatment of anaphylaxis
Sep 01, 2022: First patent issued in Europe for Orexo's adrenaline product OX640
Jul 11, 2022: Aquestive Therapeutics reports positive results from final two arms of EPIPHAST Trial Supporting performance and real-world functionality of AQST-109 Epinephrine Oral Film
Jul 05, 2022: Orexo's nasal adrenaline rescue medication OX640 enters clinical development
Jun 15, 2022: Aquestive Therapeutics reports positive initial topline data from part 3 of EPIPHAST trial evaluating AQST-109 epinephrine oral Film
Apr 12, 2022: Aquestive Therapeutics reports positive topline data from part 2 of EPIPHAST trial evaluating AQST-109 epinephrine oral film
Mar 17, 2022: Aquestive Therapeutics receives FDA Fast Track Designation for AQST-109 for emergency treatment of allergic reactions including anaphylaxis
Feb 28, 2022: ARS Pharmaceuticals to share new data at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting
Feb 28, 2022: Aquestive Therapeutics presented positive topline Phase 1 results for AQST-109 epinephrine oral film at American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting
Feb 25, 2022: Aquestive Therapeutics reports positive topline data from part 1 of EPIPHAST Trial evaluating AQST-109 epinephrine oral film
Feb 24, 2022: Aquestive Therapeutics announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
Feb 01, 2022: Phase 1 trial shows epinephrine can meet therapeutic thresholds when administered sublingually
Dec 13, 2021: Aquestive Therapeutics receives written response to pre-IND submission for AQST-109 (epinephrine prodrug sublingual film) and begins recruitment for its epinephrine film pharmacokinetic and safety trial (EPIPHAST)
Dec 02, 2021: Orexo develops a nasal adrenaline medication based on the novel amorphOX platform
Nov 08, 2021: Hoth Therapeutics Inks API and drug product contracts with WuXi STA to advance manufacturing of HT-KIT cancer therapeutic
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Anaphylaxis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Anaphylaxis - Pipeline by Allakos Inc, 2022
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, 2022
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, 2022
Anaphylaxis - Pipeline by BioArdis LLC, 2022
Anaphylaxis - Pipeline by Bryn Pharma LLC, 2022
Anaphylaxis - Pipeline by Crossject SA, 2022
Anaphylaxis - Pipeline by Hoth Therapeutics Inc, 2022
Anaphylaxis - Pipeline by Klaria Pharma Holding AB, 2022
Anaphylaxis - Pipeline by Nasus Pharma Ltd, 2022
Anaphylaxis - Pipeline by Orexo AB, 2022
Anaphylaxis - Pipeline by Pharmacin BV, 2022
Anaphylaxis - Pipeline by PureIMS BV, 2022
Anaphylaxis - Dormant Projects, 2022

List of Figures
Number of Products under Development for Anaphylaxis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022